Risk of hepatocellular carcinoma in relation to ABO blood type

Dig Liver Dis. 2016 Jan;48(1):94-6. doi: 10.1016/j.dld.2015.10.011. Epub 2015 Oct 17.

Abstract

Background: Mortality and incidence rates of hepatocellular carcinoma (HCC) parallel the geographical distribution of hepatitis B and C viruses among the general population, however genetic factors modulate individual cancer risk.

Aims: ABO blood type, as a genetic marker, has previously been associated with the risk of several malignancies; we aimed to evaluate whether an association exists with HCC.

Methods: This is a retrospective case-control study based on ABO distribution in 194 patients with HCC, compared with 215 decompensated cirrhotics without HCC listed for liver transplantation, and 90,322 healthy blood donors.

Results: In patients with HCC, prevalence of blood type O was 35%, vs. 44% in cirrhotics (OR: 0.67, 95% CI 0.45-0.99; p=0.046) and 45% in blood donors (OR: 0.65, 95% CI 0.48-0.88; p=0.004).

Conclusions: ABO blood type non-O is associated with higher risk of hepatocellular carcinoma, compared to cirrhotics without HCC and healthy subjects.

Keywords: ABO; Blood type; Cirrhosis; Hepatocellular carcinoma.

MeSH terms

  • ABO Blood-Group System*
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / blood*
  • Carcinoma, Hepatocellular / epidemiology*
  • Case-Control Studies
  • Female
  • Humans
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / epidemiology
  • Liver Neoplasms / blood*
  • Liver Neoplasms / epidemiology*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Young Adult

Substances

  • ABO Blood-Group System